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The kalimantacin polyketide antibiotics inhibit fatty acid 
biosynthesis in Staphylococcus aureus by targeting the enoyl-
acyl carrier protein binding site of FabI 
Christopher D Fage†, Thomas Lathouwers†, Michiel Vanmeert, Ling-Jie Gao, Kristof Vrancken, 
Eveline-Marie Lammens, Angus NM Weir, Ruben Degroote, Harry Cuppens, Simone Kosol, Thomas J 
Simpson, Matthew P Crump, Christine L Willis, Piet Herdewijn, Eveline Lescrinier, Rob Lavigne, Jozef 
Anné and Joleen Masschelein*
Abstract: The enoyl-acyl carrier protein reductase enzyme FabI is 
essential for fatty acid biosynthesis in Staphylococcus aureus and 
represents a promising target for the development of novel, urgently 
needed anti-staphylococcal agents. Here, we elucidate the mode of 
action of the kalimantacin antibiotics, a novel class of FabI inhibitors 
with clinically-relevant activity against multidrug-resistant S. aureus. 
By combining X-ray crystallography with molecular dynamics 
simulations, in vitro kinetic studies and chemical derivatization 
experiments, we characterize the interaction between the antibiotics 
and their target, and we demonstrate that the kalimantacins bind in a 
unique conformation that differs significantly from the binding mode 
of other known FabI inhibitors. We also investigate mechanisms of 
acquired resistance in S. aureus and identify key residues in FabI 
that stabilize the binding of the antibiotics. Our findings provide 
intriguing insights into the mode of action of a novel class of FabI 
inhibitors that will inspire future anti-staphylococcal drug 
development. 
Staphylococcus aureus is a notorious human pathogen 
responsible for a wide range of hospital- and community-
acquired infections with life-threatening complications, such as 
septicemia, pneumonia, endocarditis and meningitis.[1] The 
continuing global evolution and spread of multidrug-resistant 
strains of S. aureus, such as methicillin-resistant S. aureus 
(MRSA), remains one of the major concerns for healthcare 
institutions worldwide, and novel anti-staphylococcal agents are 
therefore urgently needed.[2] An attractive and relatively 
underexploited target for antibacterial drug development in S. 
aureus is the fatty acid biosynthetic pathway (FAS-II).[3] Fatty 
acids are essential components of cell membranes and cannot 
be scavenged from the human host.[4] Furthermore, the bacterial 
FAS-II pathway differs significantly from the mammalian FAS-I 
system, which utilizes a multi-functional, multi-domain enzyme 
rather than discrete enzymes to catalyze each step in the fatty 
acid chain elongation cycle.[5] Inhibitors of bacterial fatty acid 
biosynthesis are therefore considered to be selective and safe 
for use in humans. The most frequently targeted enzyme in the 
FAS-II pathway is the NADPH-dependent enoyl-acyl carrier 
protein (ACP) reductase (ENR) enzyme FabI, which catalyses 
the final and rate-limiting step of the elongation cycle.[6] FabI is 
essential to cell viability and is a validated drug target in S. 
aureus.[4,7] Several bacterial species have been reported to 
utilize alternative ENR isozymes, such as FabL in Bacillus 
subtilis, FabK in Streptococcus pneumoniae and FabV in Vibrio 
cholera.[8] Due to differences in secondary structure and amino 
acid composition, these isozymes are generally less sensitive to 
FabI inhibitors.[9] However, FabI is the only ENR isozyme in S. 
aureus and is therefore attracting considerable interest as a 
target for the development of narrow-spectrum antibiotics to 
treat MRSA infections. 
Kalimantacin A or batumin (KLA, 1, Figure 1A) is a 
polyketide antibiotic produced by Pseudomonas and Alcaligenes 
spp. that displays selective and clinically-relevant activity against 
staphylococci, including MRSA.[10-13] It is four- to eight-fold more 
potent than its E,E-diene isomer kalimantacin B (KLB, 2, Figure 
1A), isolated from Alcaligenes sp. YL-02632S.[12] The 
kalimantacin antibiotics are assembled by a hybrid polyketide 
synthase-nonribosomal peptide synthetase (PKS-NRPS) 
assembly line that exerts remarkable control over the 
incorporation of different b-branching modifications.[10,14] As 
linear unsaturated acids and polyenes, the kalimantacins have 
no analogues among currently used antibiotics in medical 
practice. Preliminary clinical trials with kalimantacin A, 
administered as a 0.1% ointment, have indicated that it is highly 
effective in the treatment and control of nasal S. aureus 
infections.[15] In addition, it has been shown to efficiently disrupt 
and prevent the formation of S. aureus biofilms.[16] Despite its 
promising biological activity, no further clinical development has 
been pursued due to a lack of knowledge regarding its precise 
mechanism of action. Kalimantacin A has been proposed to 
inhibit FabI in S. aureus (saFabI) based on radiolabelled 
precursor incorporation studies as well as the presence of a 
FabV-like resistant isoform in the kalimantacin biosynthetic 
operon in P. fluorescens.[17] However, no biochemical or 
structural data on its mode of action have been reported to date. 
To elucidate the molecular basis for the action of 
kalimantacin A, we pursued a crystal structure of saFabI in 
complex with the antibiotic and the redox cofactor NADPH. FabI 
was overproduced in E. coli BL21 (DE3) as an N-terminal 
hexahistidine (His6) fusion protein and purified to homogeneity 
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by nickel affinity chromatography. UHPLC-ESI-Q-TOF-MS 
analysis confirmed that the purified protein had the expected 
molecular weight (Supplementary Figure 1). Following removal 
of the His6 tag, saFabI was screened for crystals in a solution 
containing kalimantacin A and NADPH. A single crystal of a 
ternary complex diffracted to ~2.45 Å. Once reflections were 
phased via molecular replacement by searching for two saFabI 
tetramers (PDB ID 4ALI)[18] in a P212121 unit cell (Supplementary 
Table 1), electron density was clearly visible for both the 
coenzyme and inhibitor (Supplementary Figure 2). 
 
Figure 1. The polyketide antibiotics kalimantacin A and B bind in the 
hydrophobic substrate channel of FabI from S. aureus. (A) Structure of 
kalimantacin A (1) and B (2). Overall view of a (B) tetramer and (C) monomer 
of saFabI bound to kalimantacin A and NADPH. Color code: FabI chains A-D 
(teal, gold, blue and salmon, respectively), kalimantacin A (KLA, gold carbons) 
and NADPH (white carbons). SBL-1, which contains 310-helix h6, is colored 
blue in panel C. (D) Magnified views of the saFabI active site, with 
kalimantacin A- (left) and B- (right) binding residues labeled. For clarity, V201 
is hidden from the foreground. Colored as above, with kalimantacin B (KLB) 
carbons in salmon. 
With NADPH and kalimantacin A bound, FabI assembles into 
a symmetric homotetramer with nearly ~13,000 Å2 buried 
between each pair of monomers (Figure 1B),[19] an arrangement 
that has previously been observed.[18] The overall structure 
(Figure 1B-D) resembles that of saFabI in complex with NADP+ 
and triclosan, a well-known inhibitor of FabI that is widely used 
as a preservative and broad-spectrum biocide (PDB ID 4ALI, 
Figure 2A and 2C). Kalimantacin A is also located in the active 
site where the native enoyl-ACP substrate normally binds.[20] 
However, relative to triclosan, kalimantacin A occupies nearly 
twice the surface area of the active site (~445 Å2 vs. ~822 Å2, 
respectively),[19] resulting in disruption of 310-helix h6 of the 
substrate binding loop SBL-1 (Gly191-Gly203) (Figure 1C).[20] 
The antibiotic assumes an inverted w-shaped conformation, with 
its center and ends folded inward, resting above NADPH in an 
elongated binding pocket. The lipophilic alkyl moiety of 
kalimantacin A is accommodated by the hydrophobic 
environment of the “left” subpocket, whereas the heteroatom-
rich portion of the antibiotic is located in the more hydrophilic 
“right” subpocket, which opens to solvent (Figure 1D and 
Supplementary Figure 3). Kalimantacin A binds FabI primarily 
through van der Waals interactions with L102, Y147, Q155, 
N156, Y157, M160, P192, A198, V201, F204 and I207 on the 
“left” side and A95, F96, A97, M99, L196 and S197 on the “right” 
side. This binding mode differs markedly from those reported for 
other known classes of FabI inhibitors, such as diphenyl ethers, 
pyridones, benzimidazoles and naphthyridines, all of which 
contain one or more ring structures and are invariably located 
above the nicotinamide ring of the NADP(H)/NAD(H) cofactor in 
the “left” subpocket (Figure 2). 
 
Figure 2. Structures of saFabI monomers bound to representative 
inhibitors. All panels are shown from the same view after aligning chain A of 
the relevant structure with that of FabI/NADPH/kalimantacin A (see Ca r.m.s.d. 
values below). Structure of saFabI bound to (A) NADPH/kalimantacin A (PDB 
ID 6TBB), (B) NADPH/kalimantacin B (PDB ID 6TBC; Ca r.m.s.d. = 0.150 Å 
for 239 atoms), (C) NADP+/triclosan (PDB ID 4ALI; Ca r.m.s.d. = 0.192 Å for 
214 atoms),[18] (D) NADPH/CG400549 (PDB ID 4CV1; Ca r.m.s.d. = 0.221 Å 
for 203 atoms),[21] (E) NADP+/compound 8 (PDB ID 4NZ9; Ca r.m.s.d. = 0.226 
Å for 210 atoms) and (F) 3’-NADPH/AFN-1252 (PDB ID 4FS3; Ca r.m.s.d. = 
0.274 Å for 213 atoms).[22] Structures solved herein are colored teal (saFabI), 
with gold (kalimantacin A), salmon (kalimantacin B) or white (NADPH) 
carbons; other structures are colored grey (saFabI), with blue (inhibitor) or 
white (NADP(H) or analog) carbons. Inhibitor structure, name, and class are 
given at the top of each panel. 
The FabI/NADPH/kalimantacin A complex is further 
stabilized by six specific interactions. The carboxy terminus and 
adjacent vinyl group of kalimantacin A form p-stacking 
interactions with the nicotinamide ring of NADPH, further 
allowing the carboxylic acid group to form hydrogen bonds with 





the 2′-OH of the ribose moiety of NADPH (2.6 ± 0.2 Å) and the 
side chain of Y157 (2.6 ± 0.2 Å) (Figure 1D).[18] These contacts, 
which appear to be crucial for the recognition of many known 
FabI inhibitors, mimic the interactions observed with the 
thioester carbonyl of the acyl-ACP enolate intermediate during 
the reductase reaction.[20] Indeed, superposition of our structure 
with that of the Mycobacterium tuberculosis FabI ortholog bound 
to NAD+ and C16-N-acetylcysteamine (PDB ID 1BVR)[23] shows 
that kalimantacin A utilizes its unique distribution of sp2- and sp3-
hybridized carbons to closely mimic the bent conformation of the 
natural fatty acyl substrate (Figure 3). Kalimantacin A also binds 
to the backbone atoms of A97 which normally interact with the 
terminal phosphopantetheine amide in the natural substrate: the 
C-19 carbonyl oxygen atom of kalimantacin A forms a hydrogen 
bond with the amide hydrogen atom (3.0 ± 0.1 Å) while the C-17 
hydroxyl group is hydrogen bonded to the carbonyl oxygen atom 
(2.7 ± 0.2 Å). Finally, the hydrogen atoms of the carbamate NH2 
in kalimantacin A associate via hydrogen bonds with the oxygen 
atom of the backbone carbonyl in A95 (2.8 ± 0.2 Å) and the side 
chain of S197 (2.9 ± 0.1 Å), thereby forming a bridge between 
the two flexible substrate binding loops SBL-1 and SBL-2 
(residues I94-E108). Energy minimization analysis of the crystal 
structure indicates that the S197 side chain also has the 
potential to interact with the carboxylate oxygen of kalimantacin 
(~3.0 Å), further strengthening the hydrogen bonding network 
between the enzyme, cofactor and antibiotic. Like A97, S197 is 
predicted to position the phosphopantetheine amide group when 
the natural enoyl-ACP substrate binds.[20] 
 
Figure 3. Kalimantacin A binds saFabI with interactions both resembling 
and differing from those of a substrate analog. Superposition of an saFabI 
monomer bound to NADPH/KLA with an M. tuberculosis InhA (FabI ortholog) 
monomer bound to NAD+ and a C16-N-acetylcysteamine (C16-S-NAC) 
substrate analog (PDB ID 1BVR); Ca r.m.s.d. of 0.920 Å for 180 atoms). 
Colour code: saFabI (teal) bound to kalimantacin A (gold carbons) and 
NADPH (white carbons); InhA (grey) bound to C16-S-NAC (blue carbons) and 
NADP+ (white carbons). While the structures generally align well, major 
rearrangements in a few secondary structural elements near the active site 
give a diverging Ca r.m.s.d. 
To investigate the effect of kalimantacin A on the catalytic 
activity of saFabI, a series of in vitro enzymatic assays and 
kinetic studies were performed using crotonoyl-CoA as a mimic 
of the natural substrate.[18] The ability of FabI to consume 
NADPH in the presence of varying concentrations of the 
antibiotic was examined by monitoring the decrease in 
absorption at 340 nm (Figure 4A). In this assay, saFabI was 
inhibited by kalimantacin with an IC50 of 1.51 µM (Figure 4B). In 
comparison, we determined the IC50 value for triclosan as 5.71 
µM. 
 
Figure 4. Mechanism of inhibition of saFabI by kalimantacin A. (A) 
Analysis of NADPH consumption in the saFabI-catalyzed reduction of 
crotonoyl-CoA in the presence of varying concentrations of kalimantacin A. 
The absorption at 340 nm was monitored continuously for 30 min. (B) IC50 
determination of kalimantacin A. (C and D) Identification of the mechanism of 
inhibition of kalimantacin A with respect to (C) crotonoyl-CoA and (D) NADPH. 
Initial reaction velocities in the presence of 0 µM ( ), 0.91 µM (○) and 1.37 
µM (●) kalimantacin A were plotted against substrate concentrations in double 
reciprocal plots. The markers represent the mean of three independent 
replicates. Data were fitted against the Morrison equation to obtain the Ki.  
The kinetics of saFabI inhibition were analyzed by measuring 
the initial rates of NADPH oxidation. Assays were performed by 
varying the concentration of crotonoyl-CoA at a saturating 
concentration of NADPH and vice versa. The concentration of 
kalimantacin A in these reactions was varied from 0 to 1.35 µM. 
The mode of inhibition for kalimantacin A was determined by 
visualizing the kinetic data in Lineweaver-Burk plots and fitting 
the data points to the Morrison equation (Figure 3C and 3D). 
The results show that kalimantacin A is a competitive inhibitor of 
crotonoyl-CoA with a Ki of 1.45 ± 0.35 µM, and an uncompetitive 
inhibitor with respect to NADPH (Ki = 0.69 ± 0.13 µM). This 
inhibition pattern indicates that kalimantacin A binds to the 
FabI/NADPH complex to prevent substrate binding. This is in 
contrast with diphenyl ethers, such as triclosan, which bind 
exclusively to the enzyme/NADP+ complex generated by 
catalysis.[6] 
Despite its promising biological activity, little is known about 
the structure-activity relationship of kalimantacin A. Kalimantacin 
B (2, Figure 1A) has previously been reported to be produced by 
Alcaligenes sp. YL-02632S as a minor congener of 1 with four- 
to eight-fold reduced activity against S. aureus. To understand 
the structural basis for its reduced potency, we purified 
kalimantacin B from a large-scale culture of P. fluorescens 
BCCM_ID9359 for co-crystallization experiments with saFabI 
and NADPH (Supplementary Table 2 and Supplementary 
Figures 4-8). A single crystal consisting of all three components 
diffracted to ~2.55 Å (Supplementary Table 1). Interestingly, in 
spite of its lower activity, kalimantacin B was observed in the 
active site of saFabI in a conformation similar to that of 
kalimantacin A (Figure 1D). In some monomers, minor 
differences were found in the orientations of S197 and the 





carbamate group of the antibiotic, allowing for a hydrogen bond 
between the Ser side chain and bridging oxygen atom of the 
carbamate moiety (2.9 ± 0.6 Å). However, this interaction may 
also be plausible for kalimantacin A given slight bond rotations. 
Weaker electron density for kalimantacin B relative to its isomer, 
particularly in the conjugated region, suggests that kalimantacin 
B experiences greater mobility within its binding cleft 
(Supplementary Figure 2).  
To gain more insight into the binding affinities of kalimantacin 
A and B, we performed 200 ns molecular dynamics (MD) 
simulations with our co-crystal structures and calculated binding 
free energies. During the simulations, the enzyme active site 
exhibited greater flexibility in the presence of kalimantacin B 
than its E,Z-diene isomer. In the kalimantacin B complex, a 
slight displacement of the adenosine moiety in the NADPH 
cofactor was observed, along with a minor displacement of the 
substrate binding loop SBL-1 (Supplementary Figure 9). Due to 
the E,E-configuration of its diene moiety, kalimantacin B is 
unable to adopt exactly the same conformation in the active site 
as kalimantacin A. This slightly reduces its ability to clamp down 
on the NADPH cofactor. Indeed, while only a slight difference in 
calculated binding affinity was observed between both isomers, 
kalimantacin A was found to stabilize NADPH binding (DGNADPH 
= -87.95 ± 5.54 kcal/mol, DGKLA = -56.24 ± 2.34 kcal/mol) 
significantly more than kalimantacin B (DGNADPH = -68.02 ± 4.42 
kcal/mol, DGKLB = -58.16 ± 2.61 kcal/mol). 
Two other kalimantacin-related metabolites, 17-hydroxy (3) 
and 27-descarbamoyl (4) kalimantacin A, were previously 
isolated from P. fluorescens BCCM_ID9359 mutants with in-
frame deletions in the kalimantacin biosynthetic gene cluster 
(Supplementary Table 3).[10] Their activity against S. aureus 
ATCC 6538 was shown to be reduced 62.5- and 8-fold, 
respectively, compared to kalimantacin A (Minimal Inhibitory 
Concentration, MIC = 0.064 µg/ml).[10] These data indicate that 
the hydrogen bonding interactions with S197, A95 and 
especially the backbone carbonyl of A97 are essential for the 
proper positioning of the antibiotic within the FabI active site. To 
further probe the importance of functional groups for target site 
recognition, a panel of derivatives was synthesized and 
evaluated for its ability to inhibit the growth of S. aureus ATCC 
6538. Replacement of the terminal carboxylic acid group in 
kalimantacin with a carboxamide moiety (5) resulted in reduced 
potency (MIC = 2 µg/ml), while compounds with various 
substituents on the 1-OH or -NH2 group (6-8) completely lost 
their anti-staphylococcal activity (Supplementary Table 3). 
These results confirm the importance of polar interactions 
between the antibiotic and both the ribose moiety of NADPH and 
the side chain of Y157. Indeed, the same contacts are utilized by 
many known FabI inhibitors from various different compound 
classes.[20] Modification of 19-OH with an acetyl group (9) was 
also not well tolerated (MIC = 2 µg/ml) and the potency of this 
compound further decreased when the amino group of the 
carbamate moiety was replaced with a methyl group (10) (MIC = 
16 µg/ml). 
It has previously been shown that S. aureus can acquire 
resistance to kalimantacin A in vitro.[24] To investigate the 
underlying mechanism(s) of resistance development, serial 
passage experiments were performed by growing S. aureus 
NCTC 8325 on LB agar plates containing increasing 
concentrations of the antibiotic. Three independently isolated 
kalimantacin-resistant strains which could grow at 256 times the 
MIC were selected after eight serial passages. The genomic 
DNA of the three resistant strains and the parent strain was 
isolated and sequenced by highly parallel pyrosequencing. A  
  
 
Figure 5. MD simulations of saFabI(M99T) and saFabI(Y147C) in complex 
with NADPH and kalimantacin A. Superposition of the wild-type 
saFabI/NADPH/KLA complex and the corresponding (A) saFabI(M99T) and 
(B) saFabI(Y147C) complex generated by 20 ns MD simulations. Colour code: 
wild-type saFabI (teal) bound to KLA (yellow carbons) and NADPH (white 
faded carbons); mutant saFabI enzymes (grey) bound to KLA (green carbons) 
and NADPH (white carbons). R.m.s.d. plots in time (20 ns) showing the 
dynamic motion of the KLA backbone atoms in the wild-type saFabI complex 
(yellow lines), versus the mutant saFabI complexes (green lines, top and 
bottom plot, respectively) are shown below the structures. Hydrogen bond 
decomposition analyses for KLA in both mutant saFabI complexes are shown 
below each r.m.s.d. plot. 





total of six significant single nucleotide polymorphisms (SNPs) 
were identified (Supplementary Table 4). Two mutations were 
found in all kalimantacin-resistant mutants. The first mutation 
(thymine 919,922 to guanine) was located 109 nucleotides 
upstream of fabI in the promoter region (-109 T>G), while the 
second (adenine 920,470 to guanine) occurred within the fabI 
coding sequence where it caused a Tyr to Cys change at amino 
acid residue 147 (Y147C). Two other mutations were shared by 
two of the three resistant strains. One of these (thymine 920,326 
to cytosine) was also located in fabI, causing a Met to Thr 
change at amino acid residue 99 (M99T), while the other 
(adenine 919,959 to guanine) was found 72 nucleotides 
upstream of fabI (-72 A>G). The final two SNPs, which were only 
found once, were mapped to an intergenic region and a putative 
pyruvate kinase gene.  
The accumulation of point mutations in the fabI coding 
sequence and promoter region is a known resistance 
mechanism against FabI inhibitors in S. aureus. The mutations 
that occur 109 and 72 bp upstream of fabI have previously been 
identified in triclosan-resistant clinical S. aureus isolates and 
have been linked to increased fabI expression.[25] Thymine -109 
is located within the DNA recognition sequence of the 
transcriptional repressor FapR, while adenine -72 lies between 
the predicted -10 and -35 promoter sequences. Y147 is located 
in the active site of FabI and is proposed to play an essential 
role in hydration of the substrate binding pocket.[20] Replacement 
of this residue with His (Y147H) has been reported to confer 
resistance to the inhibitors triclosan, AFN-1252 and 
CG400462.[22,26] A Y147C mutation has not been observed to 
date. M99, which forms part of the flexible SBL-2 loop adjacent 
to the FabI active site, has also been found mutated in S. aureus 
isolates with decreased susceptibility to AFN-1252, and the 
combined presence of Y147H and M99T further increased the 
MIC of these antibiotics.[27]  
To confirm that the fabI mutations were responsible for the 
reduced kalimantacin susceptibility in S. aureus and to examine 
their effect on the activity of saFabI, we introduced the mutations 
in an safabI overexpression vector (pET28a-fabI), both 
separately and in the observed combination. The resulting 
saFabI variants were overproduced in E. coli and purified as 
described for the wild-type enzyme (Supplementary Figure 10). 
To investigate their catalytic activity, the consumption of NADPH 
was monitored in the presence of crotonoyl-CoA 
(Supplementary Figure 11). The Y147C mutant and the 
M99T/Y147C double mutant of saFabI showed little or no activity 
in these reactions, most likely due to protein stability issues. This 
phenomenon has previously been reported for other FabI 
mutants.[27] The M99T mutant did show activity in vitro and was 
therefore assayed for its resistance to kalimantacin. However, 
no reliable IC50 value could be obtained.  
To circumvent the challenges associated with the stability of 
the purified recombinant saFabI mutants, we utilized an in vivo 
complementation assay to examine their functionality. The wild-
type and mutant safabI genes were cloned together with the 
native safabI promoter region into the broad-host-range 
expression vector pJH10, and the resulting constructs were 
used to transform the temperature-sensitive (Ts) fabI mutant 
strain E. coli JP1111. This strain is unable to grow at the non-
permissive temperature of 42 °C unless a functional FabI 
enzyme is present.[28] As expected, heterologous expression of 
the wild-type safabI gene was able to complement the Ts fabI 
mutation of E. coli JP1111 and support its growth at the 
nonpermissive temperature (Supplementary Figure 12). 
Likewise, all saFabI mutants displayed in vivo enoyl-ACP 
reductase activity in these experiments.  
 
Table 1. Activity of kalimantacin A against S. aureus strains expressing 
wildtype or mutant safabI genes. 
Strain MIC kalimantacin A (µg/ml) 
S. aureus ATCC6538 0.064 
S. aureus RN4220  0.125 
  + pSK5632 0.125 
Native safabI promoter  
  + pSK5632(safabI) 0.125 
  + pSK5632(safabI(M99T)) 0.5 
  + pSK5632(safabI(Y147C)) 0.5 
  + pSK5632(safabI(M99T,Y147C)) 16 
(-109T>G) safabI promoter  
  + pSK5632(safabI) 0.125 
  + pSK5632(safabI(Y147C)) 4 
(-72A>G,-109T>G) safabI promoter  
  + pSK5632(safabI) 0.5 
We next examined whether the amino acid changes in 
saFabI confer resistance to kalimantacin A by determining MIC 
values against S. aureus RN4420 strains expressing the mutant 
safabI genes. For expression in S. aureus RN4220, safabI and 
the mutant variants were cloned under the control of the native 
fabI promoter in the low copy number expression vector 
pSK5632. The MIC of kalimantacin against the parental strain 
was determined as 0.125 µg/mL, and no change in MIC value 
was observed when the empty vector was introduced or when 
the wild-type safabI gene was expressed. On the other hand, 
expression of either saFabI(Y147C) or saFabI(M99T) induced a 
four-fold increase in the MIC of kalimantacin (MIC = 0.5 µg/ml), 
and RN4220 cells expressing the M99T/Y147C double mutant 
were almost completely resistant (MIC = 16 µg/ml) (Table 1). 
Upon introduction of the observed promoter mutations (-72 A>G 
and -109 T>G) into the pSK5632-safabI expression construct, 
the MIC of kalimantacin A increased four-fold. The -109 T>G 
mutation alone did not lead to an increase in resistance. 
However, when it was introduced into the safabI(Y147C) 
expression vector, an eight-fold increase in the MIC was 
observed compared to RN4420 cells carrying the construct with 
the native safabI promoter. These results are consistent with 
previous observations linking -72 A>G and -109 T>G with 
elevated safabI expression and reduced triclosan 
susceptibility.[25] 
As discussed above, both M99 and Y147 appear to 
contribute to the binding of kalimantacin A via hydrophobic 
interactions (Figure 1D). To better understand the effect of the 
mutations on kalimantacin resistance, we performed 20 ns MD 
simulations based on our structure of the saFabI/NADPH/KLA 





ternary complex (Figure 5). Simulations with tetrameric 
saFabI(M99T) revealed that the binding pose of kalimantacin A 
is disrupted after approximately 10 ns, causing the antibiotic to 
lose its interactions with key binding site residues. M99 resides 
on the flexible substrate binding loop SBL-2 that forms a 
structured lid over the active site following the binding of NADPH 
and the substrate or inhibitor. In all saFabI(M99T)/NADPH/KLA 
simulations, the lid gradually opened by 4.7 Å over the first 8 ns, 
causing kalimantacin A to drift away from the binding pocket. 
This observation is supported by r.m.s.d. plots, where an initial 
deviation of ~2 Å in the binding pose of the antibiotic is observed 
after 2 ns, followed by a 4.5 Å deviation after 10 ns. These 
results indicate that M99 plays an important role in stabilizing the 
closed conformation of SBL-2 during binding of kalimantacin A.  
In simulations with saFabI(Y147C), the binding pose of the 
antibiotic is disrupted more rapidly but less severely (Figure 5). 
The terminal carboxylic acid group loses its contacts with Y157 
and NADPH, while the carbamate moiety loses its hydrogen 
bonds to A95 and S197. This is also evident from r.m.s.d. plots, 
where the initial binding pose of kalimantacin A shifts by ~3 Å 
after 2 ns. The loss of interactions with the antibiotic triggers a 
major displacement of the adenosine moiety in the cofactor. 
Compared to the simulations with saFabI(M99T), only a minor 
opening of the SBL-2 loop (1.3 Å) is observed, and the central 
hydrophobic portion of the antibiotic largely remains inside the 
binding pocket. These results underline the importance of Y147 
in stabilizing the anchoring interactions with Y157 in saFabI and 
NADPH that keep the carboxylic acid group of kalimantacin A in 
position.  
In conclusion, we have elucidated the structural and 
mechanistic basis for the action of the kalimantacin antibiotics, 
revealing a unique mode of interaction with the essential S. 
aureus enzyme FabI. A recent study has shown that the 
biosynthetic machinery responsible for the assembly of the 
kalimantacins exerts precise control over the incorporation of the 
different b-branching modifications at C-3, C-5, C-7 and C-15 in 
the antibiotics.[14] It is now clear that the kalimantacins utilize this 
specific pattern of sp2- and sp3-hybridized carbons to mimic the 
bent conformation of the natural enoyl-ACP substrate. Our 
findings thus offer inspiration for the design and development of 
a new generation of saFabI inhibitors that can be used to 
combat the escalating public health crisis caused by multidrug-
resistant S. aureus infections. 
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